| Adler-Moore J, Lewis RE, Bruggemann RJM, Rijnders BJA, Groll AH, Walsh TJ (2019) |
| Preclinical safety, tolerability, pharmacokinetics, pharmacodynamics, and antifungal activity of liposomal amphotericin B |
| Clin Infect Dis 68 |
| pp. S244–S259 |
Candida parapsilosis, ear isolate, rice, 1 day, 200x, contrast 
Candida tropicalis, stool isolate, rice, -5 days,400x magnification. Contrast 
Geotrichum candidum, stool isolate, rice, 4 days, 200x magnification 
Saccaromyces cerevisiae, stool isolate, SG plate edge, 200x magnification |
| LAmB; liposomal amphotericin B; pharmacodynamics; pharmacokinetics; preclinical |
Causal medical examination and treatment of pathogenic fungal infections.
CONTACT